Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world's most devastating diseases. The first vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Guerin (BCG) as a prevention against TB. BCG protects against disseminated disease...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Hopkins, R, Bridgeman, A, Joseph, J, Gilbert, S, McShane, H, Hanke, T
Natura:	Journal article
Lingua:	English
Pubblicazione:	Public Library of Science 2011

Documenti analoghi

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
di: Richard Hopkins, et al.
Pubblicazione: (2011-01-01)

Vaccine strategies against tuberculosis
di: H McShane
Pubblicazione: (2009-03-01)

Vaccines for tuberculosis
di: McShane, H
Pubblicazione: (2013)

Vaccine Platform for Prevention of Mother-to-Child Transmission of HIV-1 through Breastfeeding
di: Im, E, et al.
Pubblicazione: (2008)

Insights and challenges in tuberculosis vaccine development
di: McShane, H
Pubblicazione: (2019)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
di: McShane, H
Pubblicazione: (2011)

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin
di: McShane, H
Pubblicazione: (2011)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
di: Christopher J. De Voss, et al.
Pubblicazione: (2025-02-01)

Vaccination against tuberculosis: how can we better BCG?
di: Pitt, J, et al.
Pubblicazione: (2013)

Vaccination against tuberculosis: How can we better BCG?
di: Pitt, J, et al.
Pubblicazione: (2013)

Tuberculosis vaccines: Progress and challenges
di: Checkley, A, et al.
Pubblicazione: (2011)

Vaccine strategies against tuberculosis.
di: Mcshane, H
Pubblicazione: (2009)

Developing an improved vaccine against tuberculosis.
di: Mcshane, H
Pubblicazione: (2004)

Improving tuberculosis vaccine trial efficiency: a tough nut to crack
di: McShane, H
Pubblicazione: (2023)

Why don’t we have an effective tuberculosis vaccine yet?
di: Davenne, T, et al.
Pubblicazione: (2016)

Clinical testing of tuberculosis vaccine candidates
di: Hatherill, M, et al.
Pubblicazione: (2016)

The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
di: Vermaak, S, et al.
Pubblicazione: (2023)

Replacing, reducing and refining the use of animals in tuberculosis vaccine 1 research
di: Tanner, R, et al.
Pubblicazione: (2016)

WHO preferred product characteristics for new vaccines against tuberculosis
di: Schrager, L, et al.
Pubblicazione: (2018)

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
di: Im, E, et al.
Pubblicazione: (2007)

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
di: Dockrell, HM, et al.
Pubblicazione: (2022)

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
di: Griffiths, K, et al.
Pubblicazione: (2013)

Construction and characterization of recombinant MTBVAC. HIV, a new live attenuated vaccine against HIV and tuberculosis
di: Saubi, N, et al.
Pubblicazione: (2018)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
di: Hazel M. Dockrell, et al.
Pubblicazione: (2022-05-01)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
di: Villarreal-Ramos, B, et al.
Pubblicazione: (2017)

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.
di: Sander, C, et al.
Pubblicazione: (2007)

Human and Bovine Tuberculosis
di: McShane, H
Pubblicazione: (2016)

MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice
di: Broset, E, et al.
Pubblicazione: (2019)

Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
di: Bridgeman, A, et al.
Pubblicazione: (2009)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
di: Esther Broset, et al.
Pubblicazione: (2019-06-01)

Identification of antigens presented by MHC for vaccines against tuberculosis
di: Bettencourt, P, et al.
Pubblicazione: (2020)

Identification of antigens presented by MHC for vaccines against tuberculosis
di: Bettencourt, P, et al.
Pubblicazione: (2020)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
di: Stylianou, E, et al.
Pubblicazione: (2019)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
di: Dean, G, et al.
Pubblicazione: (2014)

MVA as a vector for vaccines against HIV-1.
di: Im, E, et al.
Pubblicazione: (2004)

Engineering a dual vaccine against COVID-19 and tuberculosis
di: Carlyn Monèt Guthrie, et al.
Pubblicazione: (2023-10-01)

Controlled human infection models: is it really feasible to give people tuberculosis?
di: McShane, H
Pubblicazione: (2020)

Local pulmonary immunological biomarkers in tuberculosis
di: Morrison, H, et al.
Pubblicazione: (2021)

Local Pulmonary Immunological Biomarkers in Tuberculosis
di: Hazel Morrison, et al.
Pubblicazione: (2021-03-01)

Tuberculosis vaccines in clinical trials.
di: Rowland, R, et al.
Pubblicazione: (2011)